A record number of new oncology drugs have been approved every year, addressing the unique challenges faced by cancer patients. However, oncology is always a thought-provoking area for research and development despite having numerous approved therapies. Many pharmaceuticals are working on oncology and are trying to address the complexity of the disease. We have global…

The US FDA has approved 4 NDAs and 1 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 10 novel products in 2022 In Feb 2022, the major highlights drugs were Enjaymo for cold agglutinin disease, Fleqsuvy for spasticity associated with multiple sclerosis,…

Insights+ Key Biosimilars Events of January 2022 Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of January,…

Shots: The 40th Annual J.P. Morgan Healthcare Conference took place virtually on Jan 10-13, 2022. The premier conference is the most extensive and most informative health care investment symposium in the Healthcare and pharma sector, which connects global leaders, emerging companies, innovative technology creators, and members of the investment community Considering the top biopharma companies…

Shots: Roche was at the top with 32 deals for a total announced deal value of ~$25.83B with multiple biopharma companies The highest value deal was Roche’s AI pact with Recursion valued at up to ~$12B to identify and develop up to 40 new medications in neuroscience and oncology indications Pfizer and Merck are two…

Shots: AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021. Merck and Pfizer are among the…